Camrelizumab plus CAPOX with camrelizumab based maintenance versus CAPOX alone as initial treatment for gastric or gastro-oesophageal junction adenocarcinoma: randomised phase 3 trial. (bmj.com)

Authors: Peng Z … Shen L Journal: BMJ Published: 2026-03-12 DOI: https://doi.org/10.1136/bmj-2025-086115